SDGR
b2k 5 Star Rating
Management – 4 Stars
Science – 3 Stars
Manufacturing – 5 Stars
Potential – 5 Stars
Valuation – 1 Stars
Balance Sheet – 4 Stars
Total = 3.66 Stars
Management
Ramy Farid: Good
Very Good Speaker
Communicates Ideas Well
Engages in Conferences Often
Seems to Know the Science Well
Unknown About His Business Decision Skills
Unknown About level of Trust
Science
Science Rank: Unknown
Platform
Discovery
5 drugs in pipeline (0 commercial)
No clinical success
0 breakthrough therapies
Manufacturing
Manufacturing Rank: Outstanding
CMO Manufacturing
Cheap, Fast and Easy manufacturing
Safe, Reliable and
Scalable manufacturing
They come in Pill form
Easy for Distribution and Administration
They are extremely profitable
Potential
Software Sales = $130 million for 2021
MALT 1:
Estimate $750 million for NHL
CDC7:
Estimate $1 billion in solid tumors
WEE1:
Estimate $1 billion in solid tumors
Partnership with BMY:
Estimate $5 billion in potential for KRAS and HIF-2a
@ 10% royalty = $500 million royalties
Total Sales and Royalties = $3.25 billion
* 5 P/S = $16.2 billion Market Cap @ 61,574,088 Shares Outstanding = $263.09 Peak Value
Valuation
Software Sales = $130 million * 14 = $1.82 billion value
MALT1 - $750 million * 10% for discovery = $75 million value
CDC7 - $1 billion * 10% for discovery = $100 million value
WEE1 - $1 billion * 10% for discovery = $100 million value
BMY partnership = $500 million royalty value
Cash = $616 million
Total Value = $3.211 billion @ 61,574,088 Shares Outstanding = $52.14 Current Value
Balance Sheet
Cash = $616 million
Debt = $0
Cash Burn = 100 million per year
More than 2 years cash
Last Updated 8/17/2021
